View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 2, 2022

Kintor begins dosing Phase II androgenic alopecia treatment trial in US

The change from baseline in non-vellus target area hair counts at week 24 is the primary endpoint of the trial.

Kintor Pharmaceutical has dosed the first subject in the Phase II clinical trial of KX-826 (pyrilutamide) to treat male androgenetic alopecia (AGA) in the US.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An androgen receptor (AR) antagonist, KX-826 is a topical drug to treat AGA and acne vulgaris. 

The randomised, double-blind, placebo-controlled, parallel-group trial will assess the safety and efficacy of KX-826 to treat AGA in nearly 120 adult males

The change from baseline in non-vellus target area hair counts (TAHC) at week 24 is the trial’s primary endpoint.

In July last year, the US Food and Drug Administration had granted approval to commence phase II trial of KX-826 for AGA in the country. 

The company reported that the Phase II trial of KX-826 in adult male AGA patients met the primary endpoint in September last year.

KX-826 also demonstrated safety profile. 

Kintor Pharma founder, chairman and CEO Dr Youzhi Tong said: “As a topical AR antagonist, KX-826’s Phase I and Phase Ib clinical trials in the US have demonstrated a preliminary positive safety, pharmacokinetics and tolerability profile in dosing frequency. 

“KX-826 has showed good efficacy and safety profile in the Phase II clinical trial in China for the treatment of AGA male patients. 

“We look forward to accelerating the clinical process of KX-826 and benefiting more people suffering from hair loss in China and globally.”

In February this year, the company dosed the first subject in a Phase I trial of GT20029 (gel) in the US for AGA and acne.

The double-blind, randomised, parallel-group, placebo-controlled, dose-escalation trial is designed to evaluate the safety, tolerability and pharmacokinetics of GT20029. 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena